Current news and events

Oslo University Hospital and the Norwegian Institute for Public Health to co-lead international collaboration on clinical trials for Covid-19 and future pandemics

OUS scientists involved: Inge C. Olsen and Andreas Barratt-Due (top), Marius Trøseid and Victoria C. Simensen (bottom)
OUS scientists involved: Inge C. Olsen and Andreas Barratt-Due (top), Marius Trøseid and Victoria C. Simensen (bottom)

The Covid-19 pandemic has highlighted the need for rapid and safe testing of agents to treat a high number of SARS-CoV2 infected patients globally. Oslo University Hospital will, together with The Norwegian Institute for Public Health, take part in an ambitious European initiative sponsored by the EU. The project seeks to develop a common platform for clinical trials drawing on expertise from leading hospitals, universities, and research institutions across Europe. 

ERA PerMed grant awarded to European consortium led by Sigrid S. Skånland

Sigrid S. Skånland
Sigrid S. Skånland

A European consortium coordinated by Sigrid S. Skånland, researcher at the Department of Cancer Immunology, was awarded the ERA PerMed grant cofunded by the European Commission for their project “CLL-CLUE: Tailoring the targeted treatment of chronic lymphocytic leukemia”.

ERA PerMed is a new ERA-Net Cofund aiming to promote excellence and reinforce the competitiveness of European players in precision medicine. 

Clinical trials and research projects at Oslo University Hospital related to patients with COVID-19 and SARS CoV-2 infection

On this web page you will find an overview over planned and ongoing clinical trials and other research projects at Oslo University Hospital related to COVID-19 and SARS CoV-2 infection. The information has been retrieved from applications to the regional ethics committee, the Norwegian Research Council, other funding sources, or directly from the researchers behind the projects.

A novel biomedical technology that enhances half-life and mucosal delivery

Members of the Laboratory of Adaptive Immunity and Homeostasis
Members of the Laboratory of Adaptive Immunity and Homeostasis

Ideally, protein-based biologics could be given transmucosally, rather than intravenously or subcutaneously, but the efficiency of transmucosal drug uptake is poor. In addition, many protein-based biologics hamper from short plasma half-life. 

Scientists at University of Oslo and Oslo University Hospital, in collaboration with international researchers in Italy, Germany and US, have developed a biomedical technology that solves these major challenges.

ERGO research presented at an open public meeting at Litteraturhuset

ERGO - Epilepsy Research Group of Oslo - presented their research at an open public meeting in September during the "Forskningsdagene 2020". Title of the meeting was: "Epilepsy - from basic research to modern clinical treatment".
Senior consultant, MD, PhD Kjell Heuser, discussed the role of glial cells in epilepsy. Thereafter, the PhD candidates Toni Berger, Cecilie Bugge Bakketun and Monika Mochol talked about epigentics in epilepsy (TB), how to use brain slices in the study of epilepsy (CBB) and the use of zebrafish in epilepsy research (MM) to understand basic mechanisms of epileptogenesis. 

The success story of the Norwegian SARS-CoV-2 study

Photo: Lars Petter Devik, OUS.
Photo: Lars Petter Devik, OUS.

Jan Cato Holter from the Department of Microbiology has written an article about how the Norwegian SARS-CoV-2 study in a period of 7 months has evolved to becoming a national multicenter collaboration across all health regions and partners in the global covid-19 network. The Research Council of Norway has funded the project, which has produced 10 scientific works, of which 8 have already been submitted and 4 accepted in prestigious scientific journals. Norwegian SARS-CoV-2 study is now partner in the WHO / ISARIC global covid-19 network, led by the University of Oxford, together with 562 hospitals in 42 other countries. 

The article (in Norwegian) - entitled "Covid-19 forskning – globalt samarbeid og norsk dugnadsånd" is published on the Oslo University Hospital research blog "Ekspertsykehuset".

The 2020 Oslo University Hospital Researcher Awards to Bretthauer, Hoffmann-Vold and Kristianslund

From left: Hoffmann-Vold, Bretthauer and Kristianslund
From left: Hoffmann-Vold, Bretthauer and Kristianslund

Three Oslo University Hospital scientists have received prestigous awards for their outstanding research. The major prize - the "Excellent Researcher Award" - went to Michael Bretthauer. Anna Hoffmann-Vold and Olav Kristianslund both received the "Early Career Award".

The prize money - 300.000 and 150.000 NOK respectively - is earmarked for research activities. The awards are distributed anually in order to honour excellent scientific work. The awarding process is organized by the hospital's research committee, while an external Scientific Advisory Board has evaluated the candidates. 

PNAS publication:Allows for new treatment of covid-19 patients

From left: Søren Pischke, Tom E. Mollnes and Jan C. Holter
From left: Søren Pischke, Tom E. Mollnes and Jan C. Holter

Researchers from Oslo University Hospital and Vestre Viken show that activation of the innate immune system contributes to breathing difficulties in covid-19 patients. In a study recently published in the prestigious journal "Proceedings of the National Academy of Science" they show that systemic and long-term activation of the complement system occurred in 39 Norwegian covid-19 patients who were hospitalized.

OUH scientists Søren Pischke and Jan Cato Holter are shared first authors, and Tom Erik Mollnes is last author. They have also written a populuar science article about the findings.

Industry development agreement for innovative eye syringe

Morten C. Moe (left) and Jan Teje Andersen
Morten C. Moe (left) and Jan Teje Andersen

The Department of Ophthalmology at Oslo University Hospital and the Laboratory of Adaptive Immunity and Homeostasis of both Oslo University Hospital and University of Oslo, have entered an industry development agreement with the Dutch medical device company SJJ Solutions. The collaboration has resulted in a prototype of a tailor-made syringe optimised for eye injections.


More news from the archive